Betaxolol Hydrochloride | CAS# 63659-19-8 | Selective β1-adrenoceptor antagonist

MedKoo Cat#: 317320 | Name: Betaxolol Hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Betaxolol Hydrochloride is the hydrochloride salt form of betaxolol, a β1-AR selective adrenergic receptor antagonist. Betaxolol hydrochloride acts on the heart and circulatory system and decreases cardiac contractility and rate, and cardiac output levels. When applied topically in the eye, it lowers intraocular pressure by reducing aqueous humor secretion.

Chemical Structure

Betaxolol Hydrochloride

CAS#63659-19-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 317320

Name: Betaxolol Hydrochloride

CAS#: 63659-19-8 (HCl)

Chemical Formula: C18H30ClNO3

Exact Mass: 0.0000

Molecular Weight: 343.89

Elemental Analysis: C, 62.87; H, 8.79; Cl, 10.31; N, 4.07; O, 13.96

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 350.00	2 Weeks
100mg	USD 600.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

63659-18-7 (free base) 63659-19-8 (HCl) 93221-48-8 (S-isomer free base) 116209-55-3 (S-isomer HCl)

Synonym

Betaxolol Hydrochloride; Betaxolol HCl; Betoptima; Kerlone; Betoptic; Kerlon; ALO 140102; ALO-1401-02; ALO140102

IUPAC/Chemical Name

1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol hydrochloride

InChi Key

CHDPSNLJFOQTRK-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H

SMILES Code

CC(NCC(O)COC1=CC=C(CCOCC2CC2)C=C1)C.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 343.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Al-Wadei MJ, Bakheit AH, Abdel-Aziz AA, Wani TA. Betaxolol: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2021;46:91-136. doi: 10.1016/bs.podrm.2020.07.002. Epub 2020 Aug 21. PMID: 33461701. 2: Hu J, Li H, Zhao Y, Ke Y, Rupenthal ID, Liu H, Ye J, Han X, Yang F, Li W, Lin H, Hou D. Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction. Int J Nanomedicine. 2022 Dec 3;17:5915-5931. doi: 10.2147/IJN.S382968. PMID: 36506343; PMCID: PMC9729687. 3: Goldberg I. Betaxolol. Aust N Z J Ophthalmol. 1989 Feb;17(1):9-13. doi: 10.1111/j.1442-9071.1989.tb00483.x. PMID: 2569884. 4: Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood D, Krishnadas SR, Robin AL, Gross RD, Scheib SA, Scott H, Dickerson JE; BETOPTIC S Pediatric Study Group. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009 Aug;13(4):384-90. doi: 10.1016/j.jaapos.2009.04.017. PMID: 19683191. 5: Jain K, Kumar RS, Sood S, Dhyanandhan G. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr Drug Deliv. 2013 Oct;10(5):493-9. doi: 10.2174/1567201811310050001. PMID: 23410069. 6: Harrison R. Betaxolol and timolol. Arch Ophthalmol. 1984 Oct;102(10):1424, 1426. doi: 10.1001/archopht.1984.01040031154003. PMID: 6148923. 7: Takase B, Abe Y, Nagata M, Matsui T, Hattori H, Ohsuzu F, Ishihara M, Kurita A. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother. 2005 Oct;59 Suppl 1:S158-62. doi: 10.1016/s0753-3322(05)80024-1. PMID: 16275486. 8: Auvity S, Chiadmi F, Cisternino S, Fontan JE, Schlatter J. A Rapid Stability- Indicating RP-HPLC Method for the Determination of Betaxolol Hydrochloride in Pharmaceutical Tablets. Anal Chem Insights. 2013;8:1-7. doi: 10.4137/ACI.S11256. Epub 2013 Mar 11. PMID: 23531643; PMCID: PMC3603494. 9: Burris JF, Riggs MC, Brinkley RR. Betaxolol and stuttering. Lancet. 1990 Jan 27;335(8683):223. doi: 10.1016/0140-6736(90)90311-r. PMID: 1967682. 10: Jain S. Betaxolol-associated anterior uveitis. Eye (Lond). 1994;8 ( Pt 6):708-9. doi: 10.1038/eye.1994.181. PMID: 7867841. 11: Huang W, Zhang N, Hua H, Liu T, Tang Y, Fu L, Yang Y, Ma X, Zhao Y. Preparation, pharmacokinetics and pharmacodynamics of ophthalmic thermosensitive in situ hydrogel of betaxolol hydrochloride. Biomed Pharmacother. 2016 Oct;83:107-113. doi: 10.1016/j.biopha.2016.06.024. Epub 2016 Jun 23. PMID: 27470557. 12: Pattinson TJ, Gibson CR, Manuel FK, Bishop SL, March WF. The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. Aviat Space Environ Med. 1999 Oct;70(10):1012-7. PMID: 10519481. 13: Allam A, Elsabahy M, El Badry M, Eleraky NE. Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma. Int J Pharm. 2021 Apr 1;598:120380. doi: 10.1016/j.ijpharm.2021.120380. Epub 2021 Feb 17. PMID: 33609725. 14: Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry. 1998 Mar;10(1):9-14. doi: 10.1023/a:1026146528290. PMID: 9622045. 15: Li CX, Li H, Zhou YC, Gong ZC, Ling B. Application of topical betaxolol to cure superficial infantile hemangioma: A pilot study. Pediatr Int. 2022 Jan;64(1):e15384. doi: 10.1111/ped.15384. PMID: 36222187. 16: Lešták J, Fůs M, Weissová I, Marešová K. Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. Cesk Slov Oftalmol. 2020 Spring;76(2):94-97. English. doi: 10.31348/2020/17. PMID: 33126804. 17: Glasser SP, Friedman R, Talibi T, Smith LK, Weir EK. Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. Am J Cardiol. 1994 Feb 1;73(4):213-8. doi: 10.1016/0002-9149(94)90221-6. PMID: 8296748. 18: Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990 Jul;40(1):75-90. doi: 10.2165/00003495-199040010-00005. PMID: 2202584. 19: Huang Y, Tao Q, Hou D, Hu S, Tian S, Chen Y, Gui R, Yang L, Wang Y. A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride. Int J Nanomedicine. 2017 Mar 2;12:1731-1745. doi: 10.2147/IJN.S122747. PMID: 28280338; PMCID: PMC5340245. 20: Sajid Chughtai FR, Zaman M, Khan AH, Amjad MW, Aman W, Khan SM, Ghafoor Raja MA, Nadeem Alvi M, Afridi M, Hanif M. Formulation and evaluation of sustained release ocular inserts of betaxolol hydrochloride using arabinoxylan from Plantago ovata. Pak J Pharm Sci. 2021 May;34(3(Supplementary)):1069-1074. PMID: 34602434.